HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) – Analysts at Jefferies Financial Group issued their FY2023 earnings per share (EPS) estimates for HUTCHMED in a report issued on Tuesday, February 28th. Jefferies Financial Group analyst K. Shi anticipates that the company will post earnings of ($0.58) per share for the year. The consensus estimate for HUTCHMED’s current full-year earnings is ($1.54) per share. Jefferies Financial Group also issued estimates for HUTCHMED’s FY2024 earnings at ($0.07) EPS, FY2025 earnings at $0.03 EPS and FY2026 earnings at $0.84 EPS.
Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of HUTCHMED in a report on Wednesday.
HUTCHMED Price Performance
Hedge Funds Weigh In On HUTCHMED
Institutional investors have recently made changes to their positions in the stock. DekaBank Deutsche Girozentrale grew its holdings in shares of HUTCHMED by 107.0% during the third quarter. DekaBank Deutsche Girozentrale now owns 90,912 shares of the company’s stock valued at $766,000 after purchasing an additional 46,995 shares during the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of HUTCHMED by 156.4% during the second quarter. BNP Paribas Arbitrage SA now owns 576,308 shares of the company’s stock valued at $7,285,000 after purchasing an additional 351,516 shares during the last quarter. M&G Investment Management Ltd. grew its holdings in HUTCHMED by 22.3% in the 2nd quarter. M&G Investment Management Ltd. now owns 6,977,228 shares of the company’s stock worth $90,704,000 after buying an additional 1,272,331 shares in the last quarter. Platinum Investment Management Ltd. grew its holdings in HUTCHMED by 17.5% in the 2nd quarter. Platinum Investment Management Ltd. now owns 224,634 shares of the company’s stock worth $2,839,000 after buying an additional 33,478 shares in the last quarter. Finally, AIA Group Ltd grew its holdings in HUTCHMED by 29.3% in the 3rd quarter. AIA Group Ltd now owns 461,065 shares of the company’s stock worth $4,085,000 after buying an additional 104,425 shares in the last quarter. 22.14% of the stock is owned by institutional investors.
HUTCHMED Company Profile
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
- Get a free copy of the StockNews.com research report on HUTCHMED (HCM)
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
- Taiwan Semiconductor Manufacturing Expanding in the West
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.